Sponsor: National Institutes of Health (NIH)
Due Date: July 20, 2020
Award: This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. Application budgets are not limited but must reflect the actual needs of the proposed project. Typical budgets for these projects will normally remain less than or equal to $1,000,000 per year in total cost for U44 Phase I and $1,500,000 per year in total cost for U44 Phase II.